• Be 18-70 years old (both 18 and 70 years old), regardless of gender；

• Clinically diagnosed with stable moderate to severe plaque psoriasis with a history ≥ 6 months (from randomization), and no morphological changes in skin lesions or significant disease outbreaks as assessed by the investigator;

• Appropriate for systemic therapy or phototherapy as judged by the investigator;

• At screening and baseline, the PASI score was ≥ 12 points, the BSA ≥ 10%, and the sPGA ≥ 3 points ;

• Have a full understanding of this study, voluntarily participate in the trial, and have signed a written informed consent form;

• Subjects (including partners) are willing to voluntarily use appropriate and effective contraceptive measures from screening to 3 months after the last dose of study drug.